| Literature DB >> 27423414 |
Sylvia Hartmann1, Claudia Döring2, Claudio Agostinelli3, Soo-Jeong Portscher-Kim2, Silvia Lonardi4, Luisa Lorenzi4, Fabio Fuligni3, Daniel Martinez5, Jay Mehta6, Anita Borges6, Holger Hackstein7, Stefan Kippenberger8, Pier Paolo Piccaluga3, Ingrid Simonitsch-Klupp9, José Cabeçadas10, Elias Campo5, Fabio Facchetti4, Stefano A Pileri11, Martin-Leo Hansmann2.
Abstract
Follicular dendritic cell (FDC) sarcomas are rare mesenchymal tumours, which are fatal in 20% of the patients and usually occur in secondary lymphoid organs or extranodal localizations. Due to the rareness of these tumours, only few studies have been conducted on molecular level. In the present study, we performed microRNA (miRNA) profiling of 31 FDC sarcomas and identified two subgroups, one with high miRNA expression and the other group with low miRNA expression levels. The first group showed a strong similarity to fibroblasts and myopericytomas, whereas the second group was more closely related to FDCs from Castleman's disease. Both groups showed important differences compared with myeloid-derived dendritic cells, confirming mesenchymal origin of FDCs and their derived sarcomas. The two FDC sarcoma groups did not differ on morphological grounds, mitotic activity or BRAF mutation status. However, patients of group I presented a tendency to a shorter overall survival and more frequent podoplanin expression by immunohistochemistry. The importance of these newly recognized FDC sarcoma subgroups in terms of clinical behaviour and therapeutic implications should be assessed in a larger cohort in future studies.Entities:
Keywords: BRAF; Cell of origin; Follicular dendritic cell sarcoma; Follicular dendritic cells; Podoplanin; miRNA profiling
Mesh:
Substances:
Year: 2016 PMID: 27423414 DOI: 10.1016/j.ejca.2016.06.004
Source DB: PubMed Journal: Eur J Cancer ISSN: 0959-8049 Impact factor: 9.162